Syngene Q2 FY23-24 revenue from operations up 18.5% to Rs 910 Cr
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
Lupin enters into BTA with Lupin Manufacturing Solutions
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Evonik China and Shandong Vland Biotech agreed to build a joint venture to expand their presence in gut health solutions products for farm animals globally
Animations, colors, and shapes help to improve poor situational awareness, which is responsible for 81.5% of anesthesia-related errors
The launch of Elores in Ecuador is expected to open the doors for the entry of the novel antibiotic adjuvant entity in other important Latin American countries
PFA technology is only marketed in Europe, and yet, it has been dominating the electrophysiology market by storm
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Subscribe To Our Newsletter & Stay Updated